- Novo GLP-1 pill OK’d in U.S. for heart disease risk (NVO:NYSE) Seeking Alpha
- FDA Approves Novo Nordisk’s Rybelsus Diabetes Pill to Reduce Heart Risk The Wall Street Journal
- First oral GLP-1 cuts cardiovascular risk by 14% – and it’s now FDA-approved New Atlas
- FDA approves Novo Nordisk’s oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event Yahoo Finance
- FDA OKs Rybelsus to Reduce CV Risk in T2D Medscape
Source link
